

Austin G Duffy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2048845/publications.pdf>

Version: 2024-02-01

20
papers

6,619
citations

567281

15
h-index

839539

18
g-index

20
all docs

20
docs citations

20
times ranked

12564
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma. <i>Oncologist</i> , 2022, 27, e273-e285. | 3.7 | 22 |
| 2 | Enhanced toxicity to chemoradiation in a patient with Anti-Jo-1-antisyntetase syndrome. <i>BJR case Reports</i> , 2022, 8, . | 0.2 | 0 |
| 3 | Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2318-2326. | 7.0 | 54 |
| 4 | Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer. <i>Hepatology</i> , 2019, 69, 2048-2060. | 7.3 | 77 |
| 5 | Regorafenib as second-line therapy in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 141-142. | 17.8 | 26 |
| 6 | Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017, 357, 409-413. | 12.6 | 4,945 |
| 7 | Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 545-551. | 3.7 | 624 |
| 8 | Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. <i>Cancer</i> , 2016, 122, 1757-1765. | 4.1 | 245 |
| 9 | The case for immune-based approaches in biliary tract carcinoma. <i>Hepatology</i> , 2016, 64, 1785-1791. | 7.3 | 25 |
| 10 | Hepatocellular carcinoma and immune therapy, from a clinical perspective; where are we?. <i>Hepatic Oncology</i> , 2016, 3, 183-185. | 4.2 | 2 |
| 11 | Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage. <i>Cancer Immunology Research</i> , 2015, 3, 557-566. | 3.4 | 44 |
| 12 | The yin and yang of evasion and immune activation in HCC. <i>Journal of Hepatology</i> , 2015, 62, 1420-1429. | 3.7 | 274 |
| 13 | Colorectal Cancer Survival Gains and Novel Treatment Regimens. <i>JAMA Oncology</i> , 2015, 1, 787. | 7.1 | 75 |
| 14 | Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. <i>Hepatic Oncology</i> , 2015, 2, 39-50. | 4.2 | 10 |
| 15 | Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. <i>Hepatology</i> , 2013, 57, 1068-1077. | 7.3 | 24 |
| 16 | Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 299-307. | 4.2 | 58 |
| 17 | Fibrolamellar hepatocellular carcinoma in the USA, 2000–2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database. <i>United European Gastroenterology Journal</i> , 2013, 1, 351-357. | 3.8 | 93 |
| 18 | Comparative analysis of myeloid-derived suppressor cell (MDSC) subsets in patients with gastrointestinal (GI) malignancies.. <i>Journal of Clinical Oncology</i> , 2012, 30, 228-228. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Metastatic Pancreatic Adenocarcinoma: Current Standards, Future Directions. American Journal of Therapeutics, 2010, 17, 79-85. | 0.9 | 1 |
| 20 | Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. Targeted Oncology, 2009, 4, 267-273. | 3.6 | 20 |